Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 3/20 | 0.73 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.64 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.64 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20419319 | 1.00 | ADK (0.73) | ADKMETTL3METTL14SLC29A1 | |
| SCHEMBL20419313 | 1.00 | ADK (0.73) | ADKMETTL3METTL14SLC29A1 | |
| SCHEMBL23982517 | 1.00 | ADK (0.73) | ADKMETTL3METTL14SLC29A1 | |
| SCHEMBL30689918 | 1.00 | ADK (0.73) | ADKMETTL3METTL14SLC29A1 | |
| SCHEMBL14075944 | 0.89 | ADK (0.74) | ADKMETTL3METTL14SLC29A1 | |
| SCHEMBL4422764 | 0.89 | ADK (0.74) | ADKMETTL3METTL14SLC29A1 | |
| SCHEMBL31237241 | 0.89 | ADK (0.74) | ADKMETTL3METTL14SLC29A1 | |
| SCHEMBL30047254 | 0.88 | ADK (0.73) | ADKMETTL3METTL14SLC29A1 | |
| SCHEMBL16605527 | 0.85 | ADK (0.81) | ADKMETTL3METTL14SLC29A1 | |
| SCHEMBL16363330 | 0.85 | ADK (0.81) | ADKMETTL3METTL14SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9586986-B2 | Substituted 7-deazapurine ribonucleosides for therapeutic uses | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2017-03-07 | — | — | US | disclosed |
| US-9586986-B2 | Substituted 7-deazapurine ribonucleosides for therapeutic uses | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2017-03-07 | — | — | US | disclosed |
| US-20160159844-A1 | NOVEL SUBSTITUTED 7-DEAZAPURINE RIBONUCLEOSIDES FOR THERAPEUTIC USES | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2016-06-09 | — | — | US | disclosed |
| US-20160159844-A1 | NOVEL SUBSTITUTED 7-DEAZAPURINE RIBONUCLEOSIDES FOR THERAPEUTIC USES | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159844-A1 | NOVEL SUBSTITUTED 7-DEAZAPURINE RIBONUCLEOSIDES FOR THERAPEUTIC USES | NSUN2, DUT, TYMP | ADK 418/4885METTL3 93/4885METTL14 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.